Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record.

Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.

Ribas, Antoni, Robert, Caroline, Hodi, F. Stephen, Wolchok, Jedd D., Joshua, Anthony M, Hwu, Wen-Jen, Weber, Jeffrey S., Zarour, Hassane M., Kefford, Richard, Loboda, Andrey, Albright, Andrew, Kang, Soonmo Peter, Ebbinghaus, Scot, Yearley, Jennifer, Murphy, Erin, Nebozhyn, Michael, Lunceford, Jared K., McClanahan, Terri, Ayers, Mark, Daud, Adil·2015·Journal of Clinical Oncology

Abstract

3001 Background: Immunotherapy with anti–PD-1 monoclonal antibodies such as pembrolizumab shows robust, durable antitumor activity in patients with advanced melanoma. Examining gene expression related to the immune response within the tumor may provide new insights into the molecular features associated with clinical response to these agents. We evaluated immune-related gene expression patterns in patients with melanoma enrolled in the phase Ib KEYNOTE-001 study. Methods: Baseline tumor biopsy samples from 19 patients with melanoma enrolled in KEYNOTE-001 were used as a discovery set. Results were validated using samples from 62 additional patients from KEYNOTE-001, of whom 51 were evaluable for response per RECIST v1.1 by central review. RNA was extracted from formalin-fixed paraffin-embedded tissue sections and analyzed using the NanoString nCounter. Two signatures, the “Interferon-gamma [IFNγ] 10-gene” and the “Expanded-immune 28-gene,” were pre-specified prior to linking NanoString data to clinical outcomes. Results: The overall response rate (ORR) was 47% in the validation cohort. Both the IFNγ and the expanded-immune signatures showed statistically significant associations with ORR (P = 0.047 and 0.027, respectively) and progression-free survival (P = 0.016 and 0.015). Analysis of top-ranked genes on the platform led to the discovery of two new signatures, “TCR-signaling” and “Denovo” that were enriched in T-cell markers and MHC Class I and II genes. Conclusions: Measuring immune-related biomarkers, including T-cell specific, antigen presentation–related, and IFNγ signaling–related genes, may allow for improved selection of patients likely to respond to anti–PD-1 therapy with pembrolizumab. Results are consistent with the hypothesis that clinical responses to PD-1 blockade occur in patients with a preexisting interferon-mediated adaptive immune response. Further confirmation of these new signatures in melanoma is required. Clinical trial information: NCT01295827.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.33.15_suppl.3001

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 201

Metadata

Authors
Ribas, A., Robert, C., Hodi, F. S., Wolchok, J. D., Joshua, A. M., Hwu, W.-J., Weber, J. S., Zarour, H. M., Kefford, R., Loboda, A., Albright, A., Kang, S. P., Ebbinghaus, S., Yearley, J., Murphy, E., Nebozhyn, M., Lunceford, J. K., McClanahan, T., Ayers, M., & Daud, A.
Venue
Journal of Clinical Oncology
Published
2015-05-20
Volume
33
Issue
15_suppl
Pages
3001-3001
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2309483848
Cited by
201
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. https://app.cochat.ai/papers/10.1200/jco.2015.33.15_suppl.3001
The paper
Ribas, A., Robert, C., Hodi, F. S., Wolchok, J. D., Joshua, A. M., Hwu, W.-J., Weber, J. S., Zarour, H. M., Kefford, R., Loboda, A., Albright, A., Kang, S. P., Ebbinghaus, S., Yearley, J., Murphy, E., Nebozhyn, M., Lunceford, J. K., McClanahan, T., Ayers, M., & Daud, A. (2015). Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.33.15_suppl.3001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.